Welcome! Please browse this site for a more in-depth look at the research and accomplishments of our laboratory. Although the range of projects is large, there is a central theme of using the tools of synthetic chemistry and analytical engineering problem solving to identify and answer important fundamental questions from physical and life sciences. These answers not only help us understand the principles that govern the processes we study, but they also have useful technological and medical outlets.

We believe that this diversity provides us great opportunities for making discoveries that would not exist in its absence. The cohesive nature of the group provides an exciting, collegial research environment that leads to long term friendships with labmates. We work hard together, and we play hard together.

The general theme of the lab experience is to foster creativity and to recognize significance. All members of the group are continuously presenting their work at national/international meetings, as we strongly emphasize the need for graduates of our program to be able to articulate their findings. We hope that you find this site interesting and informative.

Mark E. Davis is the Warren and Katharine Schlinger Professor of Chemical Engineering at the California Institute of Technology and a member of the Experimental Therapeutics Program of the Comprehensive Cancer Center at the City of Hope. He has over 325 scientific publications, two textbooks and over 40 patents. Professor Davis is a founding editor of CaTTech and has been an associate editor of Chemistry of Materials and the AIChE Journal. He is the recipient of numerous awards including the Colburn and Professional Progress Awards from the AIChE and the Ipatieff, Langmuir and Murphree Prizes from the ACS. Professor Davis was the first engineer to win the NSF Alan T. Waterman Award. He was elected in the National Academy of Engineering in 1997 and the National Academy of Sciences in 2006. Professor Davis’ research efforts involve materials synthesis in two general areas; namely, zeolites and other solids that can be used for molecular recognition and catalysis, and polymers for the delivery of macromolecular therapeutics such as nucleic acids. He is the founder of Insert Therapeutics Inc., a company based in Pasadena, CA USA, focused on the use of cyclodextrin-containing polymers for drug delivery applications (www.insertt.com) and Calando Pharmaceuticals, Inc. (www.calandopharma.com) a company based in Duarte, CA USA that creates RNAi therapeutics. He is currently or has been a member of the scientific advisory boards of Symyx (Nasdaq: SMMX), Alnylam (Nasdaq: ALNY) and NovoDynamics.

Meet Mark's other "research" group.